Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | HemaSphere |
| Online Access: | https://doi.org/10.1002/hem3.70067 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850202489322733568 |
|---|---|
| author | Christine E. Ryan Yue Ren Svitlana Tyekucheva Jon E. Arnason Adam M. Boruchov Caron A. Jacobson David C. Fisher Hari Miskin Peter Sportelli Jennifer R. Brown Matthew S. Davids |
| author_facet | Christine E. Ryan Yue Ren Svitlana Tyekucheva Jon E. Arnason Adam M. Boruchov Caron A. Jacobson David C. Fisher Hari Miskin Peter Sportelli Jennifer R. Brown Matthew S. Davids |
| author_sort | Christine E. Ryan |
| collection | DOAJ |
| format | Article |
| id | doaj-art-ac7a0aaa586a4644acff9130673e12cc |
| institution | OA Journals |
| issn | 2572-9241 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj-art-ac7a0aaa586a4644acff9130673e12cc2025-08-20T02:11:46ZengWileyHemaSphere2572-92412025-01-0191n/an/a10.1002/hem3.70067Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemiaChristine E. Ryan0Yue Ren1Svitlana Tyekucheva2Jon E. Arnason3Adam M. Boruchov4Caron A. Jacobson5David C. Fisher6Hari Miskin7Peter Sportelli8Jennifer R. Brown9Matthew S. Davids10Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USADepartment of Data Science Dana‐Farber Cancer Institute Boston Massachusetts USADepartment of Data Science Dana‐Farber Cancer Institute Boston Massachusetts USADepartment of Medical Oncology Beth Israel Deaconess Medical Center Boston Massachusetts USACancer Institute, Nuvance Health Danbury Connecticut USADepartment of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USADepartment of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USATG Therapeutics New York USATG Therapeutics New York USADepartment of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USADepartment of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USAhttps://doi.org/10.1002/hem3.70067 |
| spellingShingle | Christine E. Ryan Yue Ren Svitlana Tyekucheva Jon E. Arnason Adam M. Boruchov Caron A. Jacobson David C. Fisher Hari Miskin Peter Sportelli Jennifer R. Brown Matthew S. Davids Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia HemaSphere |
| title | Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia |
| title_full | Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia |
| title_fullStr | Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia |
| title_full_unstemmed | Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia |
| title_short | Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia |
| title_sort | long term results of a phase 1 1b study of ibrutinib plus umbralisib for relapsed refractory chronic lymphocytic leukemia |
| url | https://doi.org/10.1002/hem3.70067 |
| work_keys_str_mv | AT christineeryan longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT yueren longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT svitlanatyekucheva longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT jonearnason longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT adammboruchov longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT caronajacobson longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT davidcfisher longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT harimiskin longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT petersportelli longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT jenniferrbrown longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia AT matthewsdavids longtermresultsofaphase11bstudyofibrutinibplusumbralisibforrelapsedrefractorychroniclymphocyticleukemia |